Review





Similar Products

her-2 ecd-fc tagged  (Sino Biological)
90
Sino Biological her-2 ecd-fc tagged
Impact of Affimers on the metabolic activity of breast cancer cell lines A range of breast cancer cell lines AU-565, SKBR3, BT-474, MDA-MB-453, MCF-7, MDA-MB-231, and ZR-75-1 were seeded one day prior to the addition of HER2-binding Affimers or HER2-binding Affimer-MMAE conjugates. Cells were incubated for a further 72 h, and metabolic activity was analyzed by AlamarBlue measurement. <t>HER-2-binding</t> Affimers did not affect metabolic activity in either HER2-positive cell lines AU-565 and BT474 or the HER-2-negative cell line MDA-MB-231 [(A) and (B)]. HER2-binding Affimers were conjugated with the cytotoxin MMAE via a cathepsin cleavable group and a PABC spacer (C). Seven breast cancer cell lines with varied HER2 expression level as measured by immunoblotting (D); representative blot shown; dotted line indicates removal of a lane containing lysates from a non-breast cancer cell line were treated with the Affimer-MMAE conjugates and showed dose-dependent inhibition of metabolic activity [(E) and (F)], the efficacy of which varied with HER2 expression level. All values were normalized to cells incubated with media alone. Data are mean ± SEM; dose-response curves were fitted using GraphPad Prism v 9.0, [Inhibitor] vs. response -- Variable slope (four parameters); n = 3 independent experiments for all panels. MMAE, monomethyl auristatin E.
Her 2 Ecd Fc Tagged, supplied by Sino Biological, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/her-2+ecd/pmc11298639-28-0-4
Average 90 stars, based on 1 article reviews
her-2 ecd-fc tagged - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
recombinant human her-2 ecd  (Anhui Anke)
90
Anhui Anke recombinant human her-2 ecd
Impact of Affimers on the metabolic activity of breast cancer cell lines A range of breast cancer cell lines AU-565, SKBR3, BT-474, MDA-MB-453, MCF-7, MDA-MB-231, and ZR-75-1 were seeded one day prior to the addition of HER2-binding Affimers or HER2-binding Affimer-MMAE conjugates. Cells were incubated for a further 72 h, and metabolic activity was analyzed by AlamarBlue measurement. <t>HER-2-binding</t> Affimers did not affect metabolic activity in either HER2-positive cell lines AU-565 and BT474 or the HER-2-negative cell line MDA-MB-231 [(A) and (B)]. HER2-binding Affimers were conjugated with the cytotoxin MMAE via a cathepsin cleavable group and a PABC spacer (C). Seven breast cancer cell lines with varied HER2 expression level as measured by immunoblotting (D); representative blot shown; dotted line indicates removal of a lane containing lysates from a non-breast cancer cell line were treated with the Affimer-MMAE conjugates and showed dose-dependent inhibition of metabolic activity [(E) and (F)], the efficacy of which varied with HER2 expression level. All values were normalized to cells incubated with media alone. Data are mean ± SEM; dose-response curves were fitted using GraphPad Prism v 9.0, [Inhibitor] vs. response -- Variable slope (four parameters); n = 3 independent experiments for all panels. MMAE, monomethyl auristatin E.
Recombinant Human Her 2 Ecd, supplied by Anhui Anke, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/her-2+ecd/rhgh/us12344646-271-5-8
Average 90 stars, based on 1 article reviews
recombinant human her-2 ecd - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
her-2 ecd  (Merck & Co)
90
Merck & Co her-2 ecd
Impact of Affimers on the metabolic activity of breast cancer cell lines A range of breast cancer cell lines AU-565, SKBR3, BT-474, MDA-MB-453, MCF-7, MDA-MB-231, and ZR-75-1 were seeded one day prior to the addition of HER2-binding Affimers or HER2-binding Affimer-MMAE conjugates. Cells were incubated for a further 72 h, and metabolic activity was analyzed by AlamarBlue measurement. <t>HER-2-binding</t> Affimers did not affect metabolic activity in either HER2-positive cell lines AU-565 and BT474 or the HER-2-negative cell line MDA-MB-231 [(A) and (B)]. HER2-binding Affimers were conjugated with the cytotoxin MMAE via a cathepsin cleavable group and a PABC spacer (C). Seven breast cancer cell lines with varied HER2 expression level as measured by immunoblotting (D); representative blot shown; dotted line indicates removal of a lane containing lysates from a non-breast cancer cell line were treated with the Affimer-MMAE conjugates and showed dose-dependent inhibition of metabolic activity [(E) and (F)], the efficacy of which varied with HER2 expression level. All values were normalized to cells incubated with media alone. Data are mean ± SEM; dose-response curves were fitted using GraphPad Prism v 9.0, [Inhibitor] vs. response -- Variable slope (four parameters); n = 3 independent experiments for all panels. MMAE, monomethyl auristatin E.
Her 2 Ecd, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/her-2+ecd/her2+ecd/pm36289916-92-13-22
Average 90 stars, based on 1 article reviews
her-2 ecd - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
soluble human her-2 ecd protein  (SPEED BioSystems)
90
SPEED BioSystems soluble human her-2 ecd protein
Impact of Affimers on the metabolic activity of breast cancer cell lines A range of breast cancer cell lines AU-565, SKBR3, BT-474, MDA-MB-453, MCF-7, MDA-MB-231, and ZR-75-1 were seeded one day prior to the addition of HER2-binding Affimers or HER2-binding Affimer-MMAE conjugates. Cells were incubated for a further 72 h, and metabolic activity was analyzed by AlamarBlue measurement. <t>HER-2-binding</t> Affimers did not affect metabolic activity in either HER2-positive cell lines AU-565 and BT474 or the HER-2-negative cell line MDA-MB-231 [(A) and (B)]. HER2-binding Affimers were conjugated with the cytotoxin MMAE via a cathepsin cleavable group and a PABC spacer (C). Seven breast cancer cell lines with varied HER2 expression level as measured by immunoblotting (D); representative blot shown; dotted line indicates removal of a lane containing lysates from a non-breast cancer cell line were treated with the Affimer-MMAE conjugates and showed dose-dependent inhibition of metabolic activity [(E) and (F)], the efficacy of which varied with HER2 expression level. All values were normalized to cells incubated with media alone. Data are mean ± SEM; dose-response curves were fitted using GraphPad Prism v 9.0, [Inhibitor] vs. response -- Variable slope (four parameters); n = 3 independent experiments for all panels. MMAE, monomethyl auristatin E.
Soluble Human Her 2 Ecd Protein, supplied by SPEED BioSystems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/her-2+ecd/gp120+iiib+protein/pm29718394-79-0-12
Average 90 stars, based on 1 article reviews
soluble human her-2 ecd protein - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
recombinant her-2/neu ecd  (ACROBiosystems)
90
ACROBiosystems recombinant her-2/neu ecd
Impact of Affimers on the metabolic activity of breast cancer cell lines A range of breast cancer cell lines AU-565, SKBR3, BT-474, MDA-MB-453, MCF-7, MDA-MB-231, and ZR-75-1 were seeded one day prior to the addition of HER2-binding Affimers or HER2-binding Affimer-MMAE conjugates. Cells were incubated for a further 72 h, and metabolic activity was analyzed by AlamarBlue measurement. <t>HER-2-binding</t> Affimers did not affect metabolic activity in either HER2-positive cell lines AU-565 and BT474 or the HER-2-negative cell line MDA-MB-231 [(A) and (B)]. HER2-binding Affimers were conjugated with the cytotoxin MMAE via a cathepsin cleavable group and a PABC spacer (C). Seven breast cancer cell lines with varied HER2 expression level as measured by immunoblotting (D); representative blot shown; dotted line indicates removal of a lane containing lysates from a non-breast cancer cell line were treated with the Affimer-MMAE conjugates and showed dose-dependent inhibition of metabolic activity [(E) and (F)], the efficacy of which varied with HER2 expression level. All values were normalized to cells incubated with media alone. Data are mean ± SEM; dose-response curves were fitted using GraphPad Prism v 9.0, [Inhibitor] vs. response -- Variable slope (four parameters); n = 3 independent experiments for all panels. MMAE, monomethyl auristatin E.
Recombinant Her 2/Neu Ecd, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/her-2+ecd/human+her2/pmc05385252-52-10-13
Average 90 stars, based on 1 article reviews
recombinant her-2/neu ecd - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
recombinant human her 2 ecd fc  (R&D Systems)
95
R&D Systems recombinant human her 2 ecd fc
Impact of Affimers on the metabolic activity of breast cancer cell lines A range of breast cancer cell lines AU-565, SKBR3, BT-474, MDA-MB-453, MCF-7, MDA-MB-231, and ZR-75-1 were seeded one day prior to the addition of HER2-binding Affimers or HER2-binding Affimer-MMAE conjugates. Cells were incubated for a further 72 h, and metabolic activity was analyzed by AlamarBlue measurement. <t>HER-2-binding</t> Affimers did not affect metabolic activity in either HER2-positive cell lines AU-565 and BT474 or the HER-2-negative cell line MDA-MB-231 [(A) and (B)]. HER2-binding Affimers were conjugated with the cytotoxin MMAE via a cathepsin cleavable group and a PABC spacer (C). Seven breast cancer cell lines with varied HER2 expression level as measured by immunoblotting (D); representative blot shown; dotted line indicates removal of a lane containing lysates from a non-breast cancer cell line were treated with the Affimer-MMAE conjugates and showed dose-dependent inhibition of metabolic activity [(E) and (F)], the efficacy of which varied with HER2 expression level. All values were normalized to cells incubated with media alone. Data are mean ± SEM; dose-response curves were fitted using GraphPad Prism v 9.0, [Inhibitor] vs. response -- Variable slope (four parameters); n = 3 independent experiments for all panels. MMAE, monomethyl auristatin E.
Recombinant Human Her 2 Ecd Fc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/her-2+ecd/Recombinant+Human+ErbB2%2FHer2+Fc+Chimera+Protein%2C+CF/pmc03249207__262_2011_1077_MOESM1_ESM-6-0-13
Average 95 stars, based on 1 article reviews
recombinant human her 2 ecd fc - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
recombinant human her 2 ecd fc chimera  (R&D Systems)
95
R&D Systems recombinant human her 2 ecd fc chimera
Impact of Affimers on the metabolic activity of breast cancer cell lines A range of breast cancer cell lines AU-565, SKBR3, BT-474, MDA-MB-453, MCF-7, MDA-MB-231, and ZR-75-1 were seeded one day prior to the addition of HER2-binding Affimers or HER2-binding Affimer-MMAE conjugates. Cells were incubated for a further 72 h, and metabolic activity was analyzed by AlamarBlue measurement. <t>HER-2-binding</t> Affimers did not affect metabolic activity in either HER2-positive cell lines AU-565 and BT474 or the HER-2-negative cell line MDA-MB-231 [(A) and (B)]. HER2-binding Affimers were conjugated with the cytotoxin MMAE via a cathepsin cleavable group and a PABC spacer (C). Seven breast cancer cell lines with varied HER2 expression level as measured by immunoblotting (D); representative blot shown; dotted line indicates removal of a lane containing lysates from a non-breast cancer cell line were treated with the Affimer-MMAE conjugates and showed dose-dependent inhibition of metabolic activity [(E) and (F)], the efficacy of which varied with HER2 expression level. All values were normalized to cells incubated with media alone. Data are mean ± SEM; dose-response curves were fitted using GraphPad Prism v 9.0, [Inhibitor] vs. response -- Variable slope (four parameters); n = 3 independent experiments for all panels. MMAE, monomethyl auristatin E.
Recombinant Human Her 2 Ecd Fc Chimera, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/her-2+ecd/Recombinant+Human+ErbB2%2FHer2+Fc+Chimera+Protein%2C+CF/pm17513761-101-23-28
Average 95 stars, based on 1 article reviews
recombinant human her 2 ecd fc chimera - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
recombinant antigen her-2-ecd  (Genentech inc)
90
Genentech inc recombinant antigen her-2-ecd
Impact of Affimers on the metabolic activity of breast cancer cell lines A range of breast cancer cell lines AU-565, SKBR3, BT-474, MDA-MB-453, MCF-7, MDA-MB-231, and ZR-75-1 were seeded one day prior to the addition of HER2-binding Affimers or HER2-binding Affimer-MMAE conjugates. Cells were incubated for a further 72 h, and metabolic activity was analyzed by AlamarBlue measurement. <t>HER-2-binding</t> Affimers did not affect metabolic activity in either HER2-positive cell lines AU-565 and BT474 or the HER-2-negative cell line MDA-MB-231 [(A) and (B)]. HER2-binding Affimers were conjugated with the cytotoxin MMAE via a cathepsin cleavable group and a PABC spacer (C). Seven breast cancer cell lines with varied HER2 expression level as measured by immunoblotting (D); representative blot shown; dotted line indicates removal of a lane containing lysates from a non-breast cancer cell line were treated with the Affimer-MMAE conjugates and showed dose-dependent inhibition of metabolic activity [(E) and (F)], the efficacy of which varied with HER2 expression level. All values were normalized to cells incubated with media alone. Data are mean ± SEM; dose-response curves were fitted using GraphPad Prism v 9.0, [Inhibitor] vs. response -- Variable slope (four parameters); n = 3 independent experiments for all panels. MMAE, monomethyl auristatin E.
Recombinant Antigen Her 2 Ecd, supplied by Genentech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/her-2+ecd/mcf7+neo+her2/10__1074_slash_jbc__m604127200-117-2-9
Average 90 stars, based on 1 article reviews
recombinant antigen her-2-ecd - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
elisa plates coated with glycosylated her-2 ecd recombinant protein  (Creative Biomolecules)
90
Creative Biomolecules elisa plates coated with glycosylated her-2 ecd recombinant protein
Impact of Affimers on the metabolic activity of breast cancer cell lines A range of breast cancer cell lines AU-565, SKBR3, BT-474, MDA-MB-453, MCF-7, MDA-MB-231, and ZR-75-1 were seeded one day prior to the addition of HER2-binding Affimers or HER2-binding Affimer-MMAE conjugates. Cells were incubated for a further 72 h, and metabolic activity was analyzed by AlamarBlue measurement. <t>HER-2-binding</t> Affimers did not affect metabolic activity in either HER2-positive cell lines AU-565 and BT474 or the HER-2-negative cell line MDA-MB-231 [(A) and (B)]. HER2-binding Affimers were conjugated with the cytotoxin MMAE via a cathepsin cleavable group and a PABC spacer (C). Seven breast cancer cell lines with varied HER2 expression level as measured by immunoblotting (D); representative blot shown; dotted line indicates removal of a lane containing lysates from a non-breast cancer cell line were treated with the Affimer-MMAE conjugates and showed dose-dependent inhibition of metabolic activity [(E) and (F)], the efficacy of which varied with HER2 expression level. All values were normalized to cells incubated with media alone. Data are mean ± SEM; dose-response curves were fitted using GraphPad Prism v 9.0, [Inhibitor] vs. response -- Variable slope (four parameters); n = 3 independent experiments for all panels. MMAE, monomethyl auristatin E.
Elisa Plates Coated With Glycosylated Her 2 Ecd Recombinant Protein, supplied by Creative Biomolecules, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/her-2+ecd/erbb2+ecd+protein/pm12682258-187-0-9
Average 90 stars, based on 1 article reviews
elisa plates coated with glycosylated her-2 ecd recombinant protein - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
glycosylated her-2 ecd recombinant protein  (Creative Biomolecules)
90
Creative Biomolecules glycosylated her-2 ecd recombinant protein
Impact of Affimers on the metabolic activity of breast cancer cell lines A range of breast cancer cell lines AU-565, SKBR3, BT-474, MDA-MB-453, MCF-7, MDA-MB-231, and ZR-75-1 were seeded one day prior to the addition of HER2-binding Affimers or HER2-binding Affimer-MMAE conjugates. Cells were incubated for a further 72 h, and metabolic activity was analyzed by AlamarBlue measurement. <t>HER-2-binding</t> Affimers did not affect metabolic activity in either HER2-positive cell lines AU-565 and BT474 or the HER-2-negative cell line MDA-MB-231 [(A) and (B)]. HER2-binding Affimers were conjugated with the cytotoxin MMAE via a cathepsin cleavable group and a PABC spacer (C). Seven breast cancer cell lines with varied HER2 expression level as measured by immunoblotting (D); representative blot shown; dotted line indicates removal of a lane containing lysates from a non-breast cancer cell line were treated with the Affimer-MMAE conjugates and showed dose-dependent inhibition of metabolic activity [(E) and (F)], the efficacy of which varied with HER2 expression level. All values were normalized to cells incubated with media alone. Data are mean ± SEM; dose-response curves were fitted using GraphPad Prism v 9.0, [Inhibitor] vs. response -- Variable slope (four parameters); n = 3 independent experiments for all panels. MMAE, monomethyl auristatin E.
Glycosylated Her 2 Ecd Recombinant Protein, supplied by Creative Biomolecules, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/her-2+ecd/erbb2+ecd+protein/pm12682258-187-5-9
Average 90 stars, based on 1 article reviews
glycosylated her-2 ecd recombinant protein - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Impact of Affimers on the metabolic activity of breast cancer cell lines A range of breast cancer cell lines AU-565, SKBR3, BT-474, MDA-MB-453, MCF-7, MDA-MB-231, and ZR-75-1 were seeded one day prior to the addition of HER2-binding Affimers or HER2-binding Affimer-MMAE conjugates. Cells were incubated for a further 72 h, and metabolic activity was analyzed by AlamarBlue measurement. HER-2-binding Affimers did not affect metabolic activity in either HER2-positive cell lines AU-565 and BT474 or the HER-2-negative cell line MDA-MB-231 [(A) and (B)]. HER2-binding Affimers were conjugated with the cytotoxin MMAE via a cathepsin cleavable group and a PABC spacer (C). Seven breast cancer cell lines with varied HER2 expression level as measured by immunoblotting (D); representative blot shown; dotted line indicates removal of a lane containing lysates from a non-breast cancer cell line were treated with the Affimer-MMAE conjugates and showed dose-dependent inhibition of metabolic activity [(E) and (F)], the efficacy of which varied with HER2 expression level. All values were normalized to cells incubated with media alone. Data are mean ± SEM; dose-response curves were fitted using GraphPad Prism v 9.0, [Inhibitor] vs. response -- Variable slope (four parameters); n = 3 independent experiments for all panels. MMAE, monomethyl auristatin E.

Journal: iScience

Article Title: Affimer reagents enable targeted delivery of therapeutic agents and RNA via virus-like particles

doi: 10.1016/j.isci.2024.110461

Figure Lengend Snippet: Impact of Affimers on the metabolic activity of breast cancer cell lines A range of breast cancer cell lines AU-565, SKBR3, BT-474, MDA-MB-453, MCF-7, MDA-MB-231, and ZR-75-1 were seeded one day prior to the addition of HER2-binding Affimers or HER2-binding Affimer-MMAE conjugates. Cells were incubated for a further 72 h, and metabolic activity was analyzed by AlamarBlue measurement. HER-2-binding Affimers did not affect metabolic activity in either HER2-positive cell lines AU-565 and BT474 or the HER-2-negative cell line MDA-MB-231 [(A) and (B)]. HER2-binding Affimers were conjugated with the cytotoxin MMAE via a cathepsin cleavable group and a PABC spacer (C). Seven breast cancer cell lines with varied HER2 expression level as measured by immunoblotting (D); representative blot shown; dotted line indicates removal of a lane containing lysates from a non-breast cancer cell line were treated with the Affimer-MMAE conjugates and showed dose-dependent inhibition of metabolic activity [(E) and (F)], the efficacy of which varied with HER2 expression level. All values were normalized to cells incubated with media alone. Data are mean ± SEM; dose-response curves were fitted using GraphPad Prism v 9.0, [Inhibitor] vs. response -- Variable slope (four parameters); n = 3 independent experiments for all panels. MMAE, monomethyl auristatin E.

Article Snippet: HER-2 ECD-FC tagged , Sino Biologicals , Cat#10004-H04H.

Techniques: Activity Assay, Binding Assay, Incubation, Expressing, Western Blot, Inhibition

Journal: iScience

Article Title: Affimer reagents enable targeted delivery of therapeutic agents and RNA via virus-like particles

doi: 10.1016/j.isci.2024.110461

Figure Lengend Snippet:

Article Snippet: HER-2 ECD-FC tagged , Sino Biologicals , Cat#10004-H04H.

Techniques: Virus, Recombinant, Software